<DOC>
	<DOCNO>NCT01090037</DOCNO>
	<brief_summary>In Chronic Renal Failure ( CRF ) patient primary glomerular disease nephrosclerosis primary disease : - To confirm superiority TRK-100STP placebo - To determine recommend therapeutic dose 2 dose TRK-100STP - To assess safety TRK-100STP</brief_summary>
	<brief_title>TRK-100STP Clinical Study - Chronic Renal Failure ( Primary Glomerular Disease/Nephrosclerosis )</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Nephrosclerosis</mesh_term>
	<mesh_term>Beraprost</mesh_term>
	<mesh_term>Epoprostenol</mesh_term>
	<criteria>The CRF patient primary glomerular disease nephrosclerosis primary disease The patient progressive CRF The patient secondary glomerular disease The patient CRF cause pyelonephritis , interstitial/tubular nephritis , gouty kidney , polycystic kidney disease , nephroureterolithiasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>ESRD</keyword>
	<keyword>Chronic Renal Failure</keyword>
	<keyword>Prostaglandin</keyword>
	<keyword>Prostacyclin</keyword>
	<keyword>Asian Multinational Study</keyword>
</DOC>